Media Coverage

''NIH Superbug Outbreak Highlights Lack of New Antibiotics''


"As doctors battled a deadly, drug-resistant superbug at the National Institutes of Health’s Clinical Center last year, they turned to an antibiotic of last resort.

But colistin, as it’s called, is not a fancy new creation of modern biotechnology. It was discovered in a beaker of fermenting bacteria in Japan — in 1949.

That doctors have resorted to such an old, dangerous drug — colistin causes kidney damage — highlights the lack of new antibiotics coming out of the pharmaceutical pipeline even in the face of a global epidemic of hospital-acquired bugs that quickly grow resistant to the toughest drugs.

It’s a case of evolution outrunning capitalism.

Between 1945 and 1968, drug companies invented 13 new categories of antibiotics, said Allan Coukell, director of medical programs at the Pew Health Group.

Between 1968 and today, just two new categories of antibiotics have arrived."

Full article

Date added:
Aug 28, 2012

Related Resources

The Super Bugs Causing Unmet Need and the Drugs to Fight Them

Issue Brief

Testing new antibiotics to treat highly resistant bacterial infections is especially difficult, since only a small number of patients contract such infections or meet the requirements to participate in clinical trials. Following are examples of hard-to-treat pathogens that present the greatest unmet needs today, and the types of drugs that are most likely to address them.

More

Pew Testimony Before The President’s Council of Advisors on Science and Technology

Other Resource

The President’s Council of Advisors on Science and Technology held a public meeting on April 4 to discuss the issue of antimicrobial resistance. Drug safety and innovation director Elizabeth Jungman testified on the need to spur the development of new antibacterial drugs.

More

IDSA, Pew Support Regulatory Pathway for Antibiotic Development

Media Coverage
Today, Pew applauds increasing bipartisan support in Congress to spur antibiotic development and meet the needs of patients facing the growing threat of drug-resistant pathogens. More

Tracking the Pipeline of Antibiotics in Development

Other Resource

Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. According to a Centers for Disease Control and Prevention report, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and 23,000 of them die. Doctors routinely encounter patients with infections that do not respond to available treatment, and when new drugs come to market, bacteria quickly develop resistance. To ensure that the supply of new antibiotics keeps pace with these evolving pathogens, it is necessary to have a robust pipeline of new drugs and innovative pathways to get this medicine to the patients who need it the most

More

From Lab Bench to Bedside: A Backgrounder on Drug Development

Other Resource

The process of creating new medicines is complex, time-consuming, and costly. Moving a potential therapy from concept to market can take between 10 and 15 years and cost developers as much as $1 billion. Indeed, industry also bears the cost of failure: For every drug that ultimately receives approval from the U.S. Food and Drug Administration, some 5,000 to 10,000 compounds don’t make it through the process.

More

Antibiotics Currently in Clinical Development

Other Resource
As of February 2014, there are at least 45 new antibiotics with the potential to treat serious bacterial infections in clinical development for the U.S. market. The success rate for drug development is low; at best, only 1 in 5 candidates that enter human testing will be approved for patients. This snapshot of the antibiotic pipeline will be updated periodically as products advance or are known to drop out of development. More

Pew, 31 Other Organizations Send Letter of Support for the ADAPT Act

Other Resource
The Pew Charitable Trusts sent a letter to Representatives Phil Gingrey (R-GA) and Gene Green (D-TX) of qualified support of the Antibiotic Development to Advance Patient Treatment (ADAPT) Act, a welcome step towards establishing a new regulatory pathway to bring desperately-needed antibiotics to the patients who need them most. The letter was also signed by 31 organizations representing healthcare providers, hospitals, pharmacists, clinical laboratory scientists and medical microbiologists, public health experts, patients and advocates. More

'ADAPT': A Regulatory Pathway to Develop Antibiotics and Fight Drug Resistant Infections

Other Resource
On Dec. 12, 2013, a bipartisan bill was introduced in the U.S. House of Representatives to encourage development of antibiotics for patients with serious or life-threatening bacterial infections. The new legislation would direct the U.S. Food and Drug Administration, or FDA, to approve new antibiotics and antifungal drugs for specific, limited populations of patients who have infections for which few or no suitable options exist. More

To Take on Superbugs, Prime the Antibiotics Pipeline

Opinion

In the State of the Union address, President Barack Obama recognized the need to “stay ahead of drug-resistant bacteria” and that developing therapies to fight these threats is an opportunity for American innovation and discovery. The threat of drug-resistant bacteria is real, and the need for antibiotic development clear.

More

MRSA, Football, and Industrial Farms

MRSA, or methicillin-resistant Staphylococcus aureus, is a type of bacteria that can infect a person’s skin, bones, lungs, heart, brain, and blood. Unlike common staph, MRSA does not respond to traditional antibiotics such as penicillin, making it more difficult and costlier to treat, and more lethal.
More

Superbug Showdown

Like rivals on the gridiron, superbugs and antibiotic drugs are battling for supremacy. Check out the players on Team Antibiotic and Team Superbug. More

Biocentury: Reps. Introduce Bill for Antibiotic Approval Pathway, Breakpoints

Media Coverage

A bipartisan group of representatives introduced in the U.S. House of Representatives a bill that would create an accelerated approval pathway for antibiotics and antifungals for use in limited populations and would update the criteria that HHS uses to determine breakpoints for drugs.

More

Letter from Pew Thanking Representatives Gingrey and Green for Leadership on New Antibiotics Legislation

Issue Brief
Representatives Phil Gingrey (R-GA) and Gene Green (D-TX) introduced legislation intended to bring antibiotics to patients with few other treatment options. In a letter, Pew called the bill, named the Antibiotic Development to Advance Patient Treatment (ADAPT) Act, “a welcome step towards establishing a new regulatory pathway to bring desperately-needed antibiotics to the patients who need them the most.” More

Getting Smart is a Group Effort: Addressing the Crisis of Antibiotic Resistance

Opinion
More and more, we hear about drug-resistant bacteria—superbugs that few, if any, available therapies can kill. Recently, the Centers for Disease Control and Prevention, or CDC, released a report warning that infections from these pathogens result in at least 2 million illnesses and 23,000 deaths every year in the United States. More

GAIN: How a New Law is Stimulating the Development of Antibiotics

Other Resource

On July 9, 2012, the Generating Antibiotic Incentives Now, or GAIN, provisions were signed into law by President Barack Obama as part of the Food and Drug Administration Safety and Innovation Act. This bipartisan legislation extends by five years the exclusivity period during which certain antibiotics—those that treat serious or life-threatening infections—can be sold without generic competition. This additional period of exclusivity increases the potential for profits from new antibiotics by giving innovative companies more time to recoup their investment costs.

More